Cytokinetics Management
Management criteria checks 3/4
Cytokinetics' CEO is Robert Blum, appointed in Feb 2006, has a tenure of 18.17 years. total yearly compensation is $8.75M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth $22.12M. The average tenure of the management team and the board of directors is 3.1 years and 13.4 years respectively.
Key information
Robert Blum
Chief executive officer
US$8.8m
Total compensation
| CEO salary percentage | 9.0% |
| CEO tenure | 18.2yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.1yrs |
| Board average tenure | 13.4yrs |
Recent management updates
Recent updates
Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Jan 12An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued
Oct 05
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
May 07Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
Mar 03Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 20Newsflash: Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Revenue Forecasts
Dec 15Cytokinetics: Surprise Adcomm For Omecamtiv Causing Concern
Oct 17Cytokinetics gets monitoring panel's nod to continue phase 3 trial of ALS drug reldesemtiv
Oct 10Cytokinetics (NASDAQ:CYTK) Has Debt But No Earnings; Should You Worry?
Aug 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$9m | US$790k | -US$526m |
| Sep 30 2023 | n/a | n/a | -US$527m |
| Jun 30 2023 | n/a | n/a | -US$540m |
| Mar 31 2023 | n/a | n/a | -US$431m |
| Dec 31 2022 | US$9m | US$742k | -US$389m |
| Sep 30 2022 | n/a | n/a | -US$282m |
| Jun 30 2022 | n/a | n/a | -US$216m |
| Mar 31 2022 | n/a | n/a | -US$258m |
| Dec 31 2021 | US$6m | US$709k | -US$215m |
| Sep 30 2021 | n/a | n/a | -US$229m |
| Jun 30 2021 | n/a | n/a | -US$156m |
| Mar 31 2021 | n/a | n/a | -US$135m |
| Dec 31 2020 | US$5m | US$682k | -US$127m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$140m |
| Mar 31 2020 | n/a | n/a | -US$132m |
| Dec 31 2019 | US$3m | US$656k | -US$122m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$110m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$3m | US$630k | -US$106m |
| Sep 30 2018 | n/a | n/a | -US$120m |
| Jun 30 2018 | n/a | n/a | -US$131m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$3m | US$612k | -US$128m |
Compensation vs Market: Robert's total compensation ($USD8.75M) is about average for companies of similar size in the US market ($USD8.30M).
Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.
CEO
Robert Blum (59 yo)
18.2yrs
Tenure
US$8,751,057
Compensation
Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and serves as its Principal Financial Officer. Mr. Blum previously served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 18.2yrs | US$8.75m | 0.32% $ 22.1m | |
| VP & Chief Accounting Officer | 4.9yrs | US$1.04m | 0.020% $ 1.3m | |
| Executive Vice President of Research & Development | 11.8yrs | US$4.44m | 0.083% $ 5.7m | |
| Executive VP & Chief Commercial Officer | 3.1yrs | US$3.20m | 0.024% $ 1.6m | |
| Co-Founder & Member of Scientific Advisory Board | 26.7yrs | US$21.94k | no data | |
| Vice President of Sales & Operations | 2.6yrs | no data | no data | |
| Vice President of Corporate Finance and Financial Planning & Analysis | less than a year | no data | no data | |
| Senior Vice President of Global Supply Chain Operations & Technical Operations | no data | no data | no data | |
| VP & Chief Compliance Officer | 2.4yrs | no data | no data | |
| VP, Associate General Counsel & Corporate Secretary | no data | no data | no data | |
| Senior Vice President of Global Marketing & Commercial Strategy | 2.9yrs | no data | no data | |
| Vice President of Human Resources | no data | no data | no data |
3.1yrs
Average Tenure
59yo
Average Age
Experienced Management: CYTK's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 17.3yrs | US$8.75m | 0.32% $ 22.1m | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$21.94k | no data | |
| Independent Director | 11.2yrs | US$529.02k | 0.0095% $ 655.4k | |
| Independent Director | 13.4yrs | US$524.02k | 0.0095% $ 655.4k | |
| Co-Founder & Chairman of Scientific Advisory Board | 16yrs | US$41.50k | no data | |
| Independent Director | 3.4yrs | US$519.02k | 0.012% $ 792.1k | |
| Independent Chairman | 15.2yrs | US$559.02k | 0.026% $ 1.8m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 7.8yrs | US$942.23k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
13.4yrs
Average Tenure
69.5yo
Average Age
Experienced Board: CYTK's board of directors are seasoned and experienced ( 13.4 years average tenure).